These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21684857)

  • 21. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
    Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
    AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
    Liu J; Chan-Tack KM; Jadhav P; Seo S; Robertson SM; Kraft J; Singer ME; Struble KA; Arya V
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):446-53. PubMed ID: 24755134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
    Antinori A; Zaccarelli M; Cingolani A; Forbici F; Rizzo MG; Trotta MP; Di Giambenedetto S; Narciso P; Ammassari A; Girardi E; De Luca A; Perno CF
    AIDS Res Hum Retroviruses; 2002 Aug; 18(12):835-8. PubMed ID: 12201905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    Pillay P; Ford N; Shubber Z; Ferrand RA
    PLoS One; 2013; 8(7):e68995. PubMed ID: 23894391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
    AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
    Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
    Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
    Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
    Taneja C; Juday T; Gertzog L; Edelsberg J; Correll T; Hebden T; Oster G
    Expert Opin Pharmacother; 2012 Oct; 13(15):2111-8. PubMed ID: 22970926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
    Pirillo M; Palmisano L; Pellegrini M; Galluzzo C; Weimer L; Bucciardini R; Fragola V; Andreotti M; Marchei E; Pichini S; Vella S; Giuliano M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):541-5. PubMed ID: 20455761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
    Haïm-Boukobza S; Morand-Joubert L; Flandre P; Valin N; Fourati S; Sayon S; Lavignon M; Simon A; Girard PM; Katlama C; Calvez V; Marcelin AG
    AIDS; 2011 Jan; 25(3):341-4. PubMed ID: 21157295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Kwara A; Ramachandran G; Swaminathan S
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):55-68. PubMed ID: 19968575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK
    AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.